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1Background—The optimal revascularization strategy in patients with multivessel disease presenting with cardiogenic shock 
complicating ST-segment–elevation myocardial infarction remains unknown.
Methods and Results—Databases were searched from 1999 to October 2016. Studies comparing immediate/single-stage 
multivessel percutaneous coronary intervention (MV-PCI) versus culprit vessel–only PCI (CO-PCI) in patients with 
multivessel disease, ST-segment–elevation myocardial infarction, and cardiogenic shock were included. Primary end 
point was short-term (in-hospital or 30 days) mortality. Secondary end points included long-term mortality, cardiovascular 
death, reinfarction, and repeat revascularization. Safety end points were in-hospital stroke, renal failure, and major 
bleeding. The meta-analysis included 11 nonrandomized studies and 5850 patients (1157 MV-PCI and 4693 CO-PCI). 
There was no significant difference in short-term mortality with MV-PCI versus CO-PCI (odds ratio [OR], 1.08; 95% 
confidence interval [CI], 0.81–1.43; P=0.61). Similarly, there were no significant differences in long-term mortality (OR, 
0.84; 95% CI, 0.54–1.30; P=0.43), cardiovascular death (OR, 0.72; 95% CI, 0.42–1.23; P=0.23), reinfarction (OR, 1.65; 
95% CI, 0.84–3.26; P=0.15), or repeat revascularization (OR, 1.13; 95% CI, 0.76–1.69; P=0.54) between the 2 groups. 
There was a nonsignificant trend toward higher in-hospital stroke (OR, 1.64; 95% CI, 0.98–2.72; P=0.06) and renal 
failure (OR, 1.30; 95% CI, 0.98–1.72; P=0.06), with no difference in major bleeding (OR, 1.47; 95% CI, 0.39–5.63; 
P=0.57) with MV-PCI when compared with CO-PCI.
Conclusions—This meta-analysis of nonrandomized studies suggests that in patients with cardiogenic shock complicating 
ST-segment–elevation myocardial infarction, there may be no significant benefit with single-stage MV-PCI compared 
with CO-PCI. Given the limitations of observational data, randomized trials are needed to determine the role of MV-PCI 
in this setting.  (Circ Cardiovasc Interv. 2017;10:e005582. DOI: 10.1161/CIRCINTERVENTIONS.117.005582.)
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2  Kolte et al  Multivessel PCI for Cardiogenic Shock
Cardiogenic shock occurs in 6% to 12% of patients with ST-segment–elevation myocardial infarction (STEMI) 
and is associated with increased mortality.1–3 The SHOCK 
trial (Should We Emergently Revascularize Occluded 
Coronaries for Cardiogenic Shock) demonstrated improved 
short- and long-term survival with early revascularization in 
patients with acute myocardial infarction (MI) and cardio-
genic shock.4,5 However, despite the increasing use of percuta-
neous coronary intervention (PCI) in these patients, mortality 
remains high at 40% to 50%.2
See Editorial by Gershlick and Banning
Multivessel coronary artery disease is present in ≤80% of 
patients with cardiogenic shock complicating STEMI and is 
associated with worse outcomes.4,6 Recent data from random-
ized controlled trials (RCTs) have shown that in patients with 
STEMI without cardiogenic shock, multivessel PCI (MV-PCI) 
compared with culprit vessel–only PCI (CO-PCI) is associ-
ated with improved clinical outcomes, but mainly driven by 
less repeat revascularization.7–10 However, no randomized 
data exist on MV-PCI versus CO-PCI in patients with car-
diogenic shock. The 2013 American College of Cardiology 
Foundation/American Heart Association guidelines for the 
management of STEMI suggests that in patients with cardio-
genic shock because of pump failure, PCI of a severe stenosis 
in a large noninfarct artery might improve hemodynamic 
stability and should be considered during the primary proce-
dure.11 Similarly, the 2014 European Society of Cardiology/
European Association for Cardio-Thoracic Surgery guidelines 
on myocardial revascularization state that multivessel PCI dur-
ing STEMI should be considered in patients with cardiogenic 
shock in the presence of multiple, critical stenoses or highly 
unstable lesions (angiographic signs of possible thrombus or 
lesion disruption), and if there is persistent ischemia after PCI 
on the supposed culprit lesion.12 These recommendations are 
largely based on theoretical considerations and extrapola-
tion of clinical trial data in hemodynamically stable STEMI 
patients, but not on nonrandomized studies in patients with 
cardiogenic shock. However, observational studies comparing 
MV-PCI versus CO-PCI in patients with cardiogenic shock 
have produced conflicting results, and the optimal revascular-
ization strategy in these patients remains unknown.1,6,13–22 In 
addition, several observational studies have included patients 
with STEMI and non-STEMI, and evidence suggests that clin-
ical profile, treatment, and outcomes are different in these 2 
groups of patients.1,3,6,15,16,22 Furthermore, prior meta-analyses 
comparing MV-PCI versus CO-PCI have included studies in 
patients with or without shock.23,24 Hence, the primary objec-
tive of our study was to perform a systematic review and meta-
analysis of studies comparing clinical outcomes of MV-PCI 
versus CO-PCI specifically in patients with cardiogenic shock 
complicating STEMI.
Methods
Data Sources
We searched PubMed, MEDLINE (Medical Literature Analysis and 
Retrieval System Online), CINHAL (Cumulative Index to Nursing 
and Allied Health Literature), Cochrane CENTRAL (Central Register 
of Controlled Trials), EMBASE (Excerpta Medica Database), Web 
of Science, and Google Scholar from August 1999 (publication of 
the pivotal SHOCK trial which demonstrated improved survival with 
early revascularization in patients with acute MI and cardiogenic 
shock) through October 2016 for English language, peer-reviewed 
publications. Conference proceedings for the Scientific Sessions of 
the American College of Cardiology, American Heart Association, 
European Society of Cardiology, Transcatheter Cardiovascular 
Therapeutics, and EuroPCR (Congress of the European Association of 
Percutaneous Cardiovascular Interventions) were also searched. The 
following key words and Medical Subject Headings (MeSH) terms 
were used: cardiogenic shock, shock, cardiogenic (MeSH), myocar-
dial infarction (MeSH), percutaneous coronary intervention (MeSH), 
percutaneous transluminal coronary angioplasty (MeSH), myocardial 
revascularization (MeSH), multivessel, multi-vessel, culprit vessel, cul-
prit-only, non-infarct, and complete revascularization. Reference lists 
of review articles, meta-analyses, and original studies identified by the 
electronic search were reviewed to find other potentially eligible stud-
ies. Authors of studies were contacted when results were unclear, rele-
vant data were not reported, or additional data were needed.1,6,13,15–18,20,22
Study Selection
Eligible studies had to fulfill the following criteria for inclusion in the 
meta-analysis: (1) study (sub)group included patients with STEMI, 
multivessel disease (MVD), and cardiogenic shock, (2) compared CO-
PCI versus immediate/single-stage MV-PCI, (3) included at least 10 pa-
tients in each treatment group, (4) >50% of the patients underwent stent 
placement, and (5) at least in-hospital/30-day mortality data (number 
of events or event rates) for the 2 treatment groups were reported or 
provided by the authors on request. Because there are no randomized 
WHAT IS KNOWN
• Recent data from randomized controlled trials have 
shown that in patients with ST-segment–elevation 
myocardial infarction without cardiogenic shock, 
multivessel percutaneous coronary intervention 
(MV-PCI) compared with culprit vessel–only PCI 
is associated with improved clinical outcomes, but 
mainly driven by less repeat revascularization.
• No randomized data exist on MV-PCI versus culprit 
vessel–only PCI in patients with cardiogenic shock, 
and observational studies have produced conflicting 
results.
WHAT THE STUDY ADDS
• In this meta-analysis of 11 nonrandomized studies 
including 5850 patients with multivessel disease, 
ST-segment–elevation myocardial infarction, and 
cardiogenic shock, there were no significant differ-
ences in short-term mortality, long-term mortality, 
cardiovascular death, reinfarction, or repeat revas-
cularization with immediate/single-stage MV-PCI 
versus culprit vessel–only PCI.
• There was a nonsignificant trend toward higher in-
hospital stroke and renal failure, but no difference in 
major bleeding with MV-PCI compared with culprit 
vessel–only PCI.
• Given the limitations of observational data, random-
ized trials are needed to determine the role of MV-
PCI in patients with cardiogenic shock complicating 
ST-segment–elevation myocardial infarction.
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studies comparing MV-PCI versus CO-PCI in patients with STEMI 
and cardiogenic shock, only nonrandomized studies and post hoc 
analyses of RCTs were included in this meta-analysis. We followed 
the PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) and MOOSE (Meta-Analysis of Observational Studies 
in Epidemiology) checklists for the protocol of our meta-analysis.25
Data Extraction and Quality Assessment
Two physician reviewers (D.K. and P.S.) independently assessed 
study eligibility, quality, and extracted data. Disagreements were re-
solved by consensus. Study quality was evaluated using the Newcastle 
Ottawa Scale, which assigns a star for 3 areas of study quality: selec-
tion (4 criteria), comparability (1 criterion), and outcome (3 criteria; 
Table I in the Data Supplement).26 Data were extracted from eligible 
studies on study design, baseline clinical characteristics, procedural 
details, and outcomes. Propensity-matched or inverse probability 
weight–adjusted data were used for the outcomes when available.
End Points
The primary end point was short-term (in-hospital or 30 days) all-
cause mortality. Secondary end points included long-term (longest 
study follow-up) mortality, cardiovascular death, reinfarction, and re-
peat revascularization. Safety end points included in-hospital stroke, 
major bleeding, and renal failure.
Statistical Analysis
Random-effects models of DerSimonian and Laird were used to cal-
culate pooled odds ratio (OR) and corresponding 95% confidence 
interval (CI) for each of the end points. Heterogeneity was assessed 
using the Higgins I2 statistic, with values <25% and >75% considered 
indicative of low and high heterogeneity, respectively. Publication bias 
was assessed visually by asymmetry in funnel plots and formally using 
Egger regression test and Begg and Mazumdar rank correlation test. 
We performed sensitivity analysis after excluding single-center stud-
ies, studies with <50% drug-eluting stent use, and studies with <1 year 
follow-up. Chronological cumulative meta-analyses were performed 
to determine whether the effect size and precision would shift based 
on the changes in treatments over the course of time. Because indi-
vidual studies included data over several years, the chronological order 
was based on the earliest year of the study period. We also conducted 
meta-regression analysis exploring the potential for effect modifica-
tion by multiple variables including age, female sex, diabetes mel-
litus, chronic kidney disease, prior MI, prior coronary artery bypass 
grafting, left ventricular ejection fraction <40%, cardiac arrest (pre- or 
intraprocedure), left main/left anterior descending coronary artery as 
culprit vessel, stent use, drug-eluting stent use, and intra-aortic balloon 
pump use on the primary end point of short-term mortality. All results 
are for MV-PCI compared with CO-PCI. All tests were 2-tailed with 
a P value of <0.05 considered significant. Analyses were performed 
using the Review Manager Version 5.3 (The Nordic Cochrane Center, 
The Cochrane Collaboration, 2014, Copenhagen, Denmark) and 
Comprehensive Meta-Analysis Version 3.0 (Biostat, Englewood, NJ).
Results
Study Selection and Description of Included Studies
The database search yielded 946 articles of which 48 full-text 
articles were assessed for eligibility (Figure 1). Conference 
abstracts for which full text was not published were excluded 
to ensure high-quality data. Finally, 11 studies were included 
in the meta-analysis. The characteristics of the included stud-
ies are shown in the Table. Of the 11 studies, 6 were retrospec-
tive, 4 were prospective, and 1 was a post hoc analysis of a 
RCT. Of the 10 nonrandomized studies, 8 were from national, 
multicenter registries, and 2 were single-center studies. In 
majority of the studies,1,14,16,17,19–22 MVD was defined as ≥50% 
stenosis in ≥2 major epicardial coronary arteries, except 2 
studies6,18 which used ≥70% as the cutoff, and 2 studies13,15 
that did not provide the exact cutoff used. The 11 studies 
included 5850 patients with STEMI, MVD, and cardiogenic 
shock. Of these, 4693 (80.2%) underwent CO-PCI and 1157 
Figure 1. PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-
Analyses) selection flow diagram. MV-PCI 
indicates multivessel percutaneous coro-
nary intervention.
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(19.8%) underwent MV-PCI during the index catheterization. 
The proportion of patients undergoing MV-PCI in individual 
studies ranged from 14.0% to 39.1%. Baseline patient and 
procedural characteristics for the 2 groups in each study are 
summarized in Tables II and III in the Data Supplement.
Short-Term Mortality
All 11 studies provided data on the primary end point of short-term 
mortality. There was no statistically significant difference in short-
term mortality with MV-PCI compared with CO-PCI (OR, 1.08; 
95% CI, 0.81–1.43; P=0.61; I2=67%; Figure 2). There was no 
evidence of publication bias (Figure IA in the Data Supplement).
Secondary End Points
Event rates at 6- and 12-month follow-up were used for analyses 
of secondary efficacy end points. The mean duration of follow-up 
weighted for the sample size was 9.8 months. There was no sig-
nificant difference in long-term mortality (OR, 0.84; 95% CI, 
0.54–1.30; P=0.43; I2=64%) or cardiovascular death (OR, 0.72; 
95% CI, 0.42–1.23; P=0.23; I2=60%) between MV-PCI versus 
CO-PCI (Figures 3 and 4). Similarly, rates of reinfarction (OR, 
1.65; 95% CI, 0.84–3.26; P=0.15; I2=2%) and repeat revascular-
ization (OR, 1.13; 95% CI, 0.76–1.69; P=0.54; I2=0%) did not 
differ significantly between the 2 groups (Figures 5 and 6).
Analyses of safety end points revealed a nonsignificant 
trend toward more in-hospital stroke (OR, 1.64; 95% CI, 
0.98–2.72; P=0.06; I2=0%) and renal failure (OR, 1.30; 95% 
CI, 0.98–1.72; P=0.06; I2=0%) with MV-PCI when compared 
with CO-PCI (Figure 7A and 7B). Major bleeding was also 
nonsignificantly higher with MV-PCI (OR, 1.47; 95% CI, 
0.39–5.63; P=0.57; I2=90%), but there was substantial het-
erogeneity likely due the different definitions of bleeding 
Figure 2. Comparison of short-term mortality after multivessel (MV) versus culprit vessel–only (CO) percutaneous coronary inter-
vention (PCI). Studies included in this analysis are Bauer et al,6 Cavender et al,13 Cavender et al,14 Hambraeus et al,15 Jaguszewski 
et al,16 Mylotte et al,18 Park et al,19 van der Schaaf et al,20 Yang et al,21 Zeymer et al,1 and Zeymer et al.22 CI indicates confidence 
interval.
Figure 3. Comparison of long-term mortality after multivessel (MV) versus culprit vessel–only (CO) percutaneous coronary intervention 
(PCI). Studies included in this analysis are Cavender et al,14 Hambraeus et al,15 Jeger et al,17 Mylotte et al,18 Park et al,19 van der Schaaf et 
al,20 Yang et al,21 and Zeymer et al.22 CI indicates confidence interval.
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7  Kolte et al  Multivessel PCI for Cardiogenic Shock
used in different studies (Figure 7C). No publication bias 
was observed for any of the secondary end points (Figure IB 
through IH in the Data Supplement).
Sensitivity Analyses, Cumulative Meta-Analyses, 
and Meta-Regression
Sensitivity analyses after excluding single-center studies and 
studies with <50% drug-eluting stent use showed similar 
results for short- and long-term mortality (Table IV in the Data 
Supplement). Similarly, there was no significant difference in 
long-term mortality with MV-PCI versus CO-PCI after exclud-
ing studies with <1 year follow-up. Chronological cumulative 
meta-analyses did not reveal a time-dependent effect for most 
end points, except cardiovascular death (Figure II in the Data 
Supplement). MV-PCI was associated with significant reduc-
tion in cardiovascular death in an earlier study, but this effect 
became nonsignificant with the addition of studies that included 
data from more recent years. Meta-regression with multiple 
covariates (as mentioned before) showed no evidence of effect 
modification by any of the variables on the primary end point 
of short-term mortality (Figure III in the Data Supplement).
Discussion
In this meta-analysis of nonrandomized studies of patients 
with cardiogenic shock complicating STEMI, we found 
no significant difference in short-term mortality, long-term 
Figure 4. Comparison of cardiovascular death after multivessel (MV) versus culprit vessel–only (CO) percutaneous coronary inter-
vention (PCI). Studies included in this analysis are Mylotte et al,18 Park et al,19 Yang et al,21 and Zeymer et al.22 CI indicates confi-
dence interval.
Figure 5. Comparison of reinfarction after multivessel (MV) versus culprit vessel–only (CO) percutaneous coronary intervention (PCI). 
Studies included in this analysis are Hambraeus et al,15 Mylotte et al,18 Park et al,19 Yang et al,21 and Zeymer et al.22 CI indicates confi-
dence interval.
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mortality, cardiovascular death, reinfarction, or repeat revas-
cularization with immediate/single-stage MV-PCI versus CO-
PCI. There was a nonsignificant trend toward higher rates of 
in-hospital stroke and renal failure with MV-PCI compared 
with CO-PCI. To our knowledge, this is the first meta-analysis 
comparing MV-PCI versus CO-PCI specifically in patients 
with cardiogenic shock complicating STEMI.
The optimal revascularization strategy (MV-PCI versus 
CO-PCI) in patients with STEMI complicated by cardiogenic 
shock remains unknown. MV-PCI of nonculprit arteries may the-
oretically limit infarct size and preserve left ventricular function, 
both of which are associated with improved survival in patients 
with acute MI.27,28 However, in our meta-analysis, immediate 
MV-PCI was not associated with reduction in short- or long-
term mortality in patients with cardiogenic shock complicating 
STEMI, compared with CO-PCI. The lack of difference may be 
related to the imbalance in baseline characteristics in nonrandom-
ized studies and the fact that we were unable to adjust for patient 
and operator characteristics which may have influenced the 
choice of revascularization strategy. Because all included studies 
were nonrandomized, it is possible that any potential benefit of 
MV-PCI was lost because patients who underwent MV-PCI were 
sicker and therefore did worse compared with those undergoing 
CO-PCI. Nonetheless, even in patients with STEMI without car-
diogenic shock, the PRAMI (Preventive Angioplasty in Acute 
Myocardial Infarction) and CvLPRIT (Complete Versus Lesion-
Only Primary PCI Pilot Study) trials showed no difference in 
all-cause mortality with immediate MV-PCI versus CO-PCI.7,9 
Similarly, previous pairwise and network meta-analyses of ran-
domized and nonrandomized studies that included patients with 
STEMI with or without cardiogenic shock have also shown 
similar or higher all-cause mortality with single-stage MV-PCI 
versus CO-PCI, but lower short- and long-term mortality with 
staged MV-PCI compared with both CO-PCI and single-stage 
MV-PCI.23,29 During our literature search for the current meta-
analysis, we found 5 studies which included patients with or 
without cardiogenic shock undergoing single-stage MV-PCI or 
staged MV-PCI.30–34 However, these studies included few patients 
and did not report outcomes separately in patients with cardio-
genic shock and those undergoing staged MV-PCI.
RCTs and meta-analyses of RCTs in patients with STEMI 
without cardiogenic shock have shown a significant reduction 
in repeat revascularization and a nonsignificant trend toward 
reduced MI with MV-PCI when compared with CO-PCI.7,35,36 
However, in patients with STEMI with cardiogenic shock, we 
found no significant difference in reinfarction or repeat revas-
cularization with MV-PCI versus CO-PCI. The end point of 
repeat revascularization is influenced by the fact that 100% of 
patients with MV-PCI undergo additional revascularization of 
the noninfarct-related arteries upfront. Successful MV-PCI may 
prevent early and late recurrent ischemia or infarction because 
of the noninfarct-related lesions. On the contrary, complicated 
or unsuccessful PCI of the noninfarct-related artery during 
MV-PCI may increase the risk of periprocedural MI because of 
distal embolization, side-branch occlusion, coronary dissection, 
no-reflow, or other procedure-related factors.37 Some of the 
challenges interventionalists might encounter while perform-
ing PCI in STEMI patients with cardiogenic shock may include 
stent undersizing because of coronary vasospasm as a result of 
concomitant administration of catecholamines and increased 
risk of thrombotic complications because of poor coronary flow. 
Similarly, patient-related factors including MVD, reduced left 
ventricular ejection fraction, and presence of systemic inflam-
mation, all of which are common in patients with cardiogenic 
shock, may also increase the risk of periprocedural MI.37
In patients with STEMI without cardiogenic shock, 
MV-PCI is not associated with an increased risk of stroke, con-
trast-induced nephropathy, or major bleeding.7–9,35 On the con-
trary, we observed a nonsignificant trend toward higher rates 
of in-hospital stroke and renal failure with MV-PCI compared 
with CO-PCI in patients with cardiogenic shock complicating 
STEMI. Although presentation with STEMI, use of intra-aortic 
Figure 6. Comparison of repeat revascularization after multivessel (MV) versus culprit vessel–only (CO) percutaneous coronary interven-
tion (PCI). Studies included in this analysis are Hambraeus et al,15 Mylotte et al,18 Park et al,19 Yang et al,21 and Zeymer et al.22 CI indicates 
confidence interval.
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balloon pump, and use of greater contrast volumes are indepen-
dent predictors of PCI-related stroke, MV-PCI is not indepen-
dently associated with an increased risk of ischemic stroke.38,39 
The nonsignificant higher stroke rate with MV-PCI in our meta-
analysis may be because of selection bias, with the potential 
that sicker patients were more likely to undergo MV-PCI. In 
addition, factors associated with PCI-related stroke such as lon-
ger procedure time and number of catheter exchanges were not 
evaluated. Further, it is difficult to diagnose stroke clinically in 
this patient population as many of them also had concomitant 
cardiac arrest and require mechanical ventilation necessitat-
ing sedation. Presentation with STEMI and cardiogenic shock 
is associated with 2- to 3-fold higher risk of developing acute 
kidney injury after PCI.40 This together with the use of higher 
amounts of contrast during MV-PCI may explain the trend 
toward higher rates of renal failure in this patient population.
Limitations
Given the lack of RCTs, this meta-analysis included only non-
randomized studies and had all limitations of observational data 
including selection bias and unmeasured confounding. In the 
studies included, the choice of revascularization strategy was 
at the operator’s discretion and was likely influenced by patient 
and operator characteristics for which we were unable to adjust 
because of the lack of patient-level data. For example, the exact 
stenosis severity was not known, and the majority of included 
studies defined MVD with a cutoff of ≥50% stenosis as opposed 
to ≥70%, meaning that a proportion of patients classified as MVD 
getting CO-PCI may in fact not have had another severe stenosis. 
This point is especially relevant, as after the SHOCK trial pub-
lication, many operators would have felt compelled to attempt 
complete revascularization in patients who truly had multiple 
severe stenoses. In addition, the influence of shock severity on 
Figure 7. Comparison of in-hospital stroke (A), renal failure (B), and major bleeding (C) after multivessel (MV) versus culprit vessel–only (CO) per-
cutaneous coronary intervention (PCI). Studies included in this analysis are Bauer et al,6 Cavender et al,13 Hambraeus et al,15 Jaguszewski et al,16 
Park et al,19 Yang et al,21 Zeymer et al,1 and Zeymer et al.22 CI indicates confidence interval.
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outcomes could not be determined.41 Moderate-to-severe hetero-
geneity was seen for some of the end points studied. The degree 
of complete revascularization in the MV-PCI group was not 
known. Our meta-analysis addresses the question of single-stage 
MV-PCI versus CO-PCI but does not provide insights into staged 
MV-PCI as a revascularization strategy in patients with cardio-
genic shock. As mentioned earlier, although we found 5 studies 
which included patients with or without cardiogenic shock who 
underwent single-stage or staged MV-PCI, none of these studies 
provided data separately in the subgroup of shock patients.30–34 
Nonetheless, it is difficult to compare CO-PCI versus staged MV-
PCI in nonrandomized studies in this particular patient popula-
tion without introducing substantial survival bias (sicker patients 
are likely to die while waiting for staged MV-PCI). Last, although 
this meta-analysis included 11 nonrandomized studies, 52.8% 
of the patients came from a single study.13
Conclusions
Notwithstanding the limitations of nonrandomized data, this 
carefully performed meta-analysis provides important evi-
dence that in patients with cardiogenic shock complicating 
STEMI, immediate/single-stage MV-PCI may not provide 
additional benefit in improving short- or long-term mortality 
beyond that offered by successful PCI of the culprit vessel 
alone. Well-designed, adequately powered RCTs are needed to 
confirm or refute these findings and to determine the optimal 
revascularization strategy in this high-risk patient population. 
The ongoing COMPLETE (Complete versus Culprit-only 
Revascularization to Treat Multivessel Disease After Primary 
PCI for STEMI [NCT01740479]) and CULPRIT-SHOCK 
(Culprit Lesion Only PCI Versus Multivessel PCI in Car-
diogenic Shock) trials will provide important answers.42 The 
COMPLETE trial will determine whether a strategy of staged 
PCI of all suitable nonculprit lesions is superior to CO-PCI 
in reducing the composite outcome of cardiovascular death 
or MI in patients with MVD and STEMI. The CULPRIT-
SHOCK trial will examine whether CO-PCI plus additional 
staged revascularization is superior to immediate/single-stage 
MV-PCI in reducing 30-day mortality and severe renal failure 
requiring renal replacement therapy in 706 acute MI (STEMI 
and non-STEMI) patients with cardiogenic shock and MVD.42
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Supplemental Tables: 
Table 1. Assessment of the Quality of Nonrandomized Studies Included in the Meta-Analysis 
Using the Newcastle-Ottawa Scale 
Study Selection Comparability Outcome 
Bauer et al. 2012
1 ÊÊÊÊ ÊÚ ÊÚÚ 
Cavender et al. 2009
2 ÊÊÊÊ ÊÊ ÊÚÚ 
Cavender et al. 2013
3 ÊÊÊÊ ÊÊ ÊÊÊ 
Hambraeus et al. 2016
4 ÊÊÊÊ ÚÚ ÊÊÊ 
Jaguszewski et al. 2013
5 ÊÊÊÊ ÚÚ ÊÊÚ 
Mylotte et al. 2013
6 ÊÊÊÊ ÊÚ ÊÊÊ 
Park et al. 2015
7 ÊÊÊÊ ÊÊ ÊÊÊ 
van der Schaaf et al. 2010
8 ÊÊÊÊ ÊÚ ÊÊÊ 
Yang et al. 2014
9 ÊÊÊÊ ÊÚ ÊÊÊ 
Zeymer et al. 2015
10 ÊÊÊÊ ÊÚ ÊÚÚ 
Zeymer et al. 2016
11 ÊÊÊÊ ÊÚ ÊÊÊ 
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Table 2. Baseline Patient and Procedural Characteristics from Nonrandomized Studies Included in the Meta-Analysis Stratified According to the 
Revascularization Strategy 
 Bauer 2012
1 
Cavender 2009
2 
Cavender 2013
3 
Hambraeus 2016
4 
Jaguszewski 2013
5 
Mylotte 2013
6 
 EHS-PCI ACC-NCDR Single Center SCAAR AMIS Plus French Multicenter 
 MV-PCI CO-PCI MV-PCI CO-PCI MV-PCI CO-PCI MV-PCI CO-PCI MV-PCI CO-PCI MV-PCI CO-PCI 
n 64 214 433 2,654 32 32 67 263 85 158 66 103 
Age, years 
66.7 ± 
12.0 
65.0 ± 
12.5 
64.4 ± 
13.0 
66.3 ± 
12.8 
64 ± 14 64 ± 15 
68.2 ± 
11.8 
71.3 ± 
10.9 
64.7 ± 
11.7 
65.0 ± 
11.2 
65.0 ± 
12.4 
68.5 ± 
11.8 
Female 28.1 32.2 35.8 35.3 31 25 32.8 34.6 22.4 25.3 34.0 28.2 
BMI, kg/m
2 
27.2 ± 4.5 27.4 ± 4.3 27.9 ± 4.5 27.1 ± 4.9 29 ± 7 27 ± 10     25.1 ± 2.7 27.0 ± 7.5 
Smoking 57.7 52.7 56.1 62.1 66 72 49.3 41.9 57.1 54.5 34.8 31.1 
Dyslipidemia 38.5 52.0 50.6 50.7   22.4 16.7 39.7 57.9 45.5 40.8 
HTN 57.9 65.0 59.8 63.4 72 69 38.8 39.5 56.5 61.1 53.0 48.5 
DM 37.3 31.6 30.5 27.3 34 22 26.9 23.6 26.1 25.0 25.8 25.2 
Prior MI 30.0 33.2 22.2 23.1 31 31 9.0 10.6   21.2 30.1 
Prior PCI 8.3 11.9 15.7 15.6 9 6 9.0 9.9 11.8 18.5 16.7 22.3 
Prior CABG 0 0 5.1 10.1 9 9 0 0 3.9 6.2 6.1 4.9 
HF 8.3 8.3 41.8 31.7   6.0 5.3 2.9 9.0   
Stroke 10.0 7.8 11.6 11.8 9 13 7.5 8.0 5.9 9.7   
PAD 5.0 9.3 8.8 11.3         
CKD 6.7 6.2 7.6 8.2 16 6 1.5 3.0 8.8 6.0   
Cardiac arrest 46.8 49.5       48.2 52.5 100 100 
LVEF     23 ± 9 27 ± 10     31.0 ± 9.6 30.3 ± 9.0 
>50% 11.4 11.9     7.5 10.3     
41-50% 8.6 12.7     9.0 13.7     
31-40% 34.3 29.9     13.4 14.4     
<30% 45.7 45.5 26.1 19.1   9.0 14.8 36.5 26.6   
             
Access site             
Femoral 95.3 97.2           
Brachial 0.0 0.5           
Radial 4.7 2.3           
4 
 
             
No. of 
stenosed 
vessels 
            
2 40.6 45.8 54.7 55.9 56 38 74.6 48.3   48.5 52.4 
3 59.4 54.2 45.3 44.1 44 18 25.4 51.3   51.5 47.6 
             
Culprit vessel             
LM     3 9     21.2 7.8 
LAD   49.4 36.8 50 50     47.0 43.7 
CX   21.5 13.7 25 25     16.7 15.5 
RCA   27.7 49.0 22 16     15.2 30.1 
Bypass graft   2.1 5.5 0 0     0 2.9 
             
Stent 89.1 84.6 84.5 97.9   100 94.7 92.2 88.0 98.5 93.2 
DES 39.1 22.4 64.7 69.4   19.4 8.4 58.2 60.3   
No. of stents 1.8 ± 1.1 1.1 ± 0.7 1.1 ± 0.8 1.4 ± 0.7   2.6 ± 1.8 1.9 ± 1.2   2.6 ± 1.1 1.6 ± 0.9 
             
Thrombectomy 17.2 16.7         39.4 39.8 
             
IABP 34.4 24.0 66.3 52.8 67 65 50.7 46.4 65.1 46.5 76.3 
Inotropes 68.9 66.3           
             
Aspirin 85.2 83.4 83.2 82.3       100 100 
Ticlopidine 3.3 0.5 0.2 0.5         
Clopidogrel 62.3 61.4 51.5 54.1       100 100 
Prasugrel             
Ticagrelor             
UFH 77.0 71.9 81.4 83.0       100 100 
LMWH 14.8 17.6 13.3 10.7         
Fondaparinux             
Bivalirudin 1.6 0.5 11.8 10.5         
GPI 54.1 53.3 79.5 79.7         
             
Procedural       100 100   80.3 75.7 
5 
 
success 
TIMI 3 62.9 71.9 82.9 89.4     87.3 85.6 81.9 77.7 
Stenosis <30-
50% 
68.8 86.3 89.6 96.8       97.0 91.3 
 
Categorical variables are presented as percentages and continuous variables as mean ± standard deviation. 
HTN = hypertension, DM = diabetes mellitus, MI = myocardial infarction, PCI = percutaneous coronary intervention, CABG = coronary artery bypass grafting, 
HF = heart failure, PAD = peripheral artery disease, CKD = chronic kidney disease, LVEF = left ventricular ejection fraction, LM = left main, LAD = left 
anterior descending coronary artery, CX = circumflex coronary artery, RCA = right coronary artery, DES = drug-eluting stent, IABP = intra-aortic balloon 
pump, UFH = unfractionated heparin, LMWH = low-molecular weight heparin, GPI = glycoprotein IIb/IIIa inhibitor, TIMI = thrombolysis in myocardial 
infarction, MV-PCI = multivessel PCI, CO-PCI = culprit vessel-only PCI, EHS-PCI = Euro Heart Survey PCI Registry, ACC-NCDR = American College of 
Cardiology- National Cardiovascular Data Registry, SCAAR = Swedish Coronary Angiography and Angioplasty Registry, AMIS Plus = Acute Myocardial 
Infarction in Switzerland Plus Registry. 
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Table 3. Baseline Patient and Procedural Characteristics from Nonrandomized Studies Included in the Meta-Analysis Stratified According to the 
Revascularization Strategy 
 Park 2015
7 
Van der Schaaf 2010
8 
Yang 2014
9 
Zeymer 2015
10 
Zeymer 2016
11 
 KAMIR Single Center KAMIR, KWGMI ALKK-PCI IABP-SHOCK II 
 MV-PCI CO-PCI MV-PCI CO-PCI MV-PCI CO-PCI MV-PCI CO-PCI MV-PCI CO-PCI 
n 83 236 37 124 60 278 121 434 109 197 
Age, years 65.3 ± 14.8 67.3 ± 14.1 67.0 ± 13.3 67.4 ± 11.4 66.1 ± 14.6 69.5 ± 13.3 66.5 ± 11.9 68.4 ± 12.1 69.8 ± 12.6 68.0 ± 14.8 
Female 29 34.2 18.9 32.3 36.7 42.1 24.0 29.5 29.4 29.3 
BMI, kg/m
2 
24.0 ± 3.0 23.3 ± 3.7     27.6 ± 4.6 27.4 ± 4.4 26.4 ± 3.6 28.1 ± 3.7 
Smoking 47.6 46.6 29.7 29.8 40.0 35.6 35.7 40.5 24.1 40.2 
Dyslipidemia 9.8 9.7 24.3 24.2 21.7 23.4 73.0 71.5 40.2 37.8 
HTN 53.7 54.5 29.7 25.8 50.0 57.9 80.5 77.5 65.7 71.4 
DM 25.6 23.3 24.3 21.8 16.5 21.7 36.5 36.8 35.8 28.1 
Prior MI     8.3 4.7 27.7 44.1 13.8 26.8 
Prior PCI   18.9 8.1 3.3 6.1 13.3 18.7 11.1 24.2 
Prior CABG   5.4 9.7 0 1.4 0 0 2.8 4.5 
HF           
Stroke       18.5 5.1 11.9 6.6 
PAD       20.3 18.0 11.9 10.1 
CKD       50.0 37.2 20.4 18.7 
Cardiac arrest 3.3 4.2   11.7 16.9 18.2 13.6 44.0 42.9 
LVEF 49.8 ± 15.6 50.3 ± 11.1   48.5 ± 15.3 45.9 ± 13.9   34.6 ± 13.7 35.0 ± 14.8 
>50%       4.5 14.9   
41-50%       22.7 17.5   
31-40%     
38.4 34.1 
19.7 19.3   
<30%     53.0 48.2   
           
Access site           
Femoral       92.6 97.5   
Brachial       1.7 0.5   
Radial       5.8 2.1   
           
7 
 
No. of 
stenosed 
vessels 
          
2 48.4 56.7 37.8 46.8 53.3 55.8 31.3 37.4 31.2 44.4 
3 46.0 39.9 62.2 53.2 46.7 44.2 68.7 62.6 68.8 55.6 
           
Culprit vessel           
LM 2.4 0.8 0.0 5.6 0 0   14.7 6.6 
LAD 31.5 25.9 56.8 43.5 40.0 38.8   47.7 43.4 
CX 16.1 7.5 16.2 18.5 5.0 8.6   14.7 17.2 
RCA 49.2 65.8 27.0 32.3 55.0 52.5   22.9 29.3 
Bypass graft 0 0 0 0 0 0   0.0 3.0 
           
Stent 100 100 70.3 61.3 96.7 94.2 90.9 85.7 97.2 91.9 
DES 83.1 82.4   88.3 83.1 23.4 15.5 48.1 39.0 
No. of stents 2.38 ± 1.09 1.32 ± 0.60   2.31 ± 1.09 1.41 ± 0.67     
           
Thrombectomy     31.7 27.7 14.7 10.3 72.5 68.2 
           
IABP 18.5 16.3 73.0 61.3 33.3 25.9 33.0 28.2 47.7 53.5 
Inotropes     81.7 81.7 59.3 56.5 95.4 89.4 
           
Aspirin     100 100 98.2 94.5 87.0 93.4 
Ticlopidine           
Clopidogrel     100 100 82.9 78.7 61.1 71.2 
Prasugrel       0 4.1 19.4 21.7 
Ticagrelor       0 0.8 7.8 5.3 
UFH       91.5 95.8 90.7 94.4 
LMWH       1.7 2.6 1.9 2.5 
Fondaparinux       0 0.5   
Bivalirudin       4.0 2.4 19.4 9.6 
GPI     18.3 25.2 61.2 62.5 54.6 52.5 
           
Procedural 
success 
96.8 95.1 94.6 80.2       
8 
 
TIMI 3 90.7 88.0 73.0 68.5 80.0 84.2 67.8 74.7 80.7 77.3 
Stenosis <30-
50% 
          
 
Categorical variables are presented as percentages and continuous variables as mean ± standard deviation. 
HTN = hypertension, DM = diabetes mellitus, MI = myocardial infarction, PCI = percutaneous coronary intervention, CABG = coronary artery bypass 
grafting, HF = heart failure, PAD = peripheral artery disease, CKD = chronic kidney disease, LVEF = left ventricular ejection fraction, LM = left main, 
LAD = left anterior descending coronary artery, CX = circumflex coronary artery, RCA = right coronary artery, DES = drug-eluting stent, IABP = 
intra-aortic balloon pump, UFH = unfractionated heparin, LMWH = low-molecular weight heparin, GPI = glycoprotein IIb/IIIa inhibitor, TIMI = 
thrombolysis in myocardial infarction, MV-PCI = multivessel PCI, CO-PCI = culprit vessel-only PCI, KAMIR = Korean Acute Myocardial Infarction 
Registry, KWGMI = Korea Working Group on Myocardial Infarction registry, ALKK-PCI = Arbeitsgemeinschaft Leitende Kardiologische 
Krankenhausärzte-PCI registry, IABP-SHOCK II = Intra-Aortic Balloon Pump in Cardiogenic Shock II.
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Table 4. Sensitivity Analyses Results for Short- and Long-Term Mortality 
 Short-Term Mortality Long-Term Mortality 
All Studies 
1.08 (0.81-1.43) 
P = 0.61, I
2
 =  67% 
0.79 (0.51-1.20) 
P = 0.20, I
2
 = 60% 
Excluding Single-Center 
Studies 
1.03 (0.75-1.43) 
P = 0.84, I
2
 =  73% 
0.70 (0.41-1.19) 
P = 0.19, I
2
 = 69% 
Excluding Studies With 
<50% DES Use 
1.27 (0.86-1.86) 
P = 0.23, I
2
 =  51% 
0.73 (0.28-1.92) 
P = 0.53, I
2
 = 55% 
Excluding Studies With <1 
Year Follow-Up 
— 
1.07 (0.73-1.57) 
P = 0.72, I
2
 = 26% 
 
Estimates are odds ratios (95% confidence interval) using random-effect models. 
DES = drug-eluting stent 
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Supplemental Figures and Figure Legends: 
 
 
Figure 1. Publication Bias Assessment 
 
 
A) Short-Term Mortality 
 
 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = -0.381818  P = 0.0866 
Egger: bias = -1.985231 (95% CI = -4.198118 to 0.227655)  P = 0.073 
Harbord-Egger: bias = -2.170399 (92.5% CI = -4.44215 to 0.101351)  P = 0.0867 
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B) Long-Term Mortality 
 
 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = -0.357143  P = 0.1789 (low power) 
Egger: bias = -1.237415 (95% CI = -5.210013 to 2.735183)  P = 0.4748 
Harbord-Egger: bias = -0.95809 (92.5% CI = -4.802415 to 2.886236)  P = 0.6112 
12 
 
C) Cardiovascular Death 
 
 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = -0.333333  P = 0.3333 (low power) 
Egger: bias = -2.250715 (95% CI = -18.606172 to 14.104742)  P = 0.6138 
Harbord-Egger: bias = -1.986646 (92.5% CI = -19.05863 to 15.085339)  P = 0.7274
13 
 
Reinfarction 
 
 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = 0  P = 0.8167 (low power) 
Egger: bias = 0.086448 (95% CI = -3.559767 to 3.732662)  P = 0.9446 
Harbord-Egger: bias = 0.847732 (92.5% CI = -4.359263 to 6.054727)  P = 0.692
14 
 
Repeat Revascularization 
 
 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = -0.4  P = 0.2333 (low power) 
Egger: bias = -1.495805 (95% CI = -11.191538 to 8.199929)  P = 0.6571 
Harbord-Egger: bias = 1.012926 (92.5% CI = -6.51552 to 8.541371)  P = 0.7422
15 
 
Stroke 
 
 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = 0.142857  P = 0.7195 (low power) 
Egger: bias = -0.061316 (95% CI = -1.315704 to 1.193072)  P = 0.9087 
Harbord-Egger: bias = 0.15828 (92.5% CI = -1.29748 to 1.61404)  P = 0.8229 
16 
 
D) Renal Failure 
 
 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = 0.066667  P > 0.9999 (low power) 
Egger: bias = 0.253726 (95% CI = -1.905845 to 2.413298)  P = 0.7606 
Harbord-Egger: bias = 0.398065 (92.5% CI = -1.573735 to 2.369865)  P = 0.6544 
17 
 
E) Major Bleeding 
 
 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = 0.333333  P = 0.3813 (low power) 
Egger: bias = -2.449104 (95% CI = -6.9277 to 2.029493)  P = 0.2188 
Harbord-Egger: bias = -3.158874 (92.5% CI = -10.406249 to 4.0885)  P = 0.3733 
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Figure 2. Chronological Cumulative Meta-Analysis 
 
A) Short-Term Mortality 
 
 
B) Long-Term Mortality 
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C) Cardiovascular Death 
 
 
 
 
D) Reinfarction 
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E) Repeat Revascularization 
 
 
 
F) Stroke 
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G) Renal Failure 
 
 
 
H) Major Bleeding 
 
 
Studies included in these analyses are Bauer et al. 2012,
1
 Cavender et al. 2009,
2
 Cavender et al. 
2014,
3
 Hambraeus et al. 2016,
4
 Jaguszewski et al. 2013,
5
 Mylotte et al. 2013,
6
 Park et al. 2015,
7
 
van der Schaaf et al. 2010,
8
 Yang et al. 2014,
9
 Zymer et al. 2015,
10
 and Zeymer et al. 2016.
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Figure 3. Meta-Regression for Short-Term Mortality 
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C) 
 
 
D)  
 
Regression of Log Odds Ratio on Diabetes Mellitus
Diabetes Mellitus
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E) 
 
 
F) 
 
Regression of Log Odds Ratio on Prior MI
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G) 
 
 
 
H)  
 
Regression of Log Odds Ratio on LVEF <40%
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I) 
 
 
 
J) 
 
Regression of Log Odds Ratio on LM/LAD Culprit
LM/LAD Culprit
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K) 
 
 
L) 
 
Regression of Log Odds Ratio on DES
DES
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M) 
 
 
 
  
Regression of Log Odds Ratio on Post-Procedure TIMI 3 Flow
Post-Procedure TIMI 3 Flow
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